RT Journal Article
SR Electronic
T1 Engineered RNA biosensors enable ultrasensitive SARS-CoV-2 detection in a simple color and luminescence assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.08.21249426
DO 10.1101/2021.01.08.21249426
A1 Chakravarthy, Anirudh
A1 Anirudh, KN
A1 George, Geen
A1 Ranganathan, Shyamsundar
A1 Shettigar, Nishan
A1 Suchitta, U
A1 Palakodeti, Dasaradhi
A1 Gulyani, Akash
A1 Ramesh, Arati
YR 2021
UL http://medrxiv.org/content/early/2021/04/16/2021.01.08.21249426.abstract
AB The continued resurgence of the COVID-19 pandemic with multiple variants underlines the need for diagnostic strategies, that are easily adapatable to the changing virus. Here, we have designed and developed toehold RNA-based sensors across the SARS-CoV-2 genome for direct and ultrasensitive detection of the virus and its prominent variants. In our assay, isothermal amplification of a fragment of SARS-CoV-2 RNA coupled with activation of our biosensors leads to a conformational switch in the sensor. This leads to translation of a reporter-protein e.g. LacZ or Nano-lantern that is easily detected using color/luminescence. By optimizing RNA-amplification and biosensor-design, we have generated a highly-sensitive diagnostic assay; with sensitivity down to attomolar SARS-CoV-2 RNA. As low as 100 copies of viral RNA are detected with development of bright color that is easily visualized by the human eye, or a simple cell phone camera as well as quantified using a spectrophotometer. This makes our assay deployable all the way from a well equiped laboratory to a low-resource setting anywhere in the world. Finally, this PHAsed NASBA-Translation Optical Method (PHANTOM) using our engineered RNA biosensors efficiently detects the presence of viral RNA in human patient samples, correlating well with Ct values from RT-qPCR tests. This work presents a powerful and universally accessible strategy for detecting Covid-19 and its prominent variants. This strategy is easily adaptable to further viral evolution and brings RNA-based bioengineering to centerstage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are profoundly grateful to support from the Azim Premji Philanthropic initiative (APPI), PNB Housing CSR funds and IQVIA. We acknowledge support from the Department of Atomic Energy, Government of India and the National Centre for Biological Sciences-TIFR, under project no. 12-R&D-TFR-5.04-0800. Research in the A.R. lab is also supported by the Human Frontier Science Program research grant RGY0077/2019 and DBT/Wellcome Trust-India Alliance (IA/I/14/2/501521). A.G. thanks University of Hyderabad, the School of Life Sciences and Department of Biochemistry (UoH) for support. Research in AG lab is also supported by Scientific and Engineering Research Board (SERB), DST, Govt. of India (EMR/2017/005093).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All clinical patient samples from nasopharyngeal swabs, which underwent real time RT-PCR testing according the ICMR guidelines, were provided by the inStem-NCBS COVID testing center. Approvals by the Institutional Human Ethics Committee (NCBS/IEC-17/002; inStem/IEC-17/001), the Institutional Biosafety Committee (TFR:NCBS:31-IBSC_UR; inStem/G-141(3)-15/CJ) and the Review Committee on Genetic Manipulation-RCGM (BT/BS/17/371/2010-PID) were obtained for conducting the RT-PCR protocols on clinical patient samples, for the presence of SARS-CoV-2 RNA. Separate RCGM approval was obtained for testing the Toehold sensors (Document No BT/IBKP/035/2019). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding authors upon reasonable request